Frontier Pharma Market by Technology Advancement and Future Scope Till 2025

Researchmoz added Most up-to-date research on "Frontier Pharma: Breast Cancer - First-in-Class Innovation Underlies Immunotherapeutic Potential and Pipeline Diversification for Late-Stage Breast Cancer" to its huge collection of research reports.

Breast cancer remains a major global healthcare concern despite exceptional levels of public awareness about the disease. A lack of clear causative environmental factors and hereditary dispositioning have resulted in the incidence of breast cancer continuing to rise, a trend which is expected to continue into the immediate future.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877885

In the UK, breast cancer is the leading type of cancer in women, with there being over 54,900 cases diagnosed each year. Although early-stage cancer is relatively treatable and has good 5- and 10-year disease-free survival rates, 10% of cancers are diagnosed late. Additionally, there are no treatments for metastatic breast cancer, which ultimately results in death.

As a whole, this presents a huge unmet clinical need in the breast cancer treatment algorithm. The treatment algorithm for breast cancer focuses on two main themes: standard chemotherapy and drugs that target hormones, namely estrogen and progesterone. However, chemotherapy and hormone drugs only make up a small percentage of the drug pipeline and an even smaller percentage of first-in-class products.

New trends in oncology are present in the breast cancer pipeline, in particular the focus on extracellular matrix degradation and improving the immune response to tumors. This report focuses on the epidemiology, pathophysiology and existing treatment options for breast cancer before giving detailed insight into promising pipeline targets and deal activity in the breast cancer market.

Scope

- Unmet need is extremely high in late-stage breast cancer.
- What are the most important etiological risk factors and pathophysiological processes implicated in breast cancer?
- What is the current treatment algorithm?
- How effective are current therapies for these indications, and how does this impact prognosis?
- The breast cancer pipeline is large and contains a very high proportion of first-in-class product innovation.
- Which molecule types and molecular targets are most prominent across the breast cancer pipeline?
- What are the relationships between established and up-coming molecular targets in breast cancer?
- Which first-in-class targets are most promising?
- How does first-in-class target diversity differ by stage of development and molecular target class?
- The deals landscape is active and dominated by very high and very low deal values.
- Which indications attract the highest deal values?

View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-breast-cancer-first-in-class-innovation-underlies-immunotherapeutic-potential-and-pipeline-diversification-for-late-stage-breast-cancer-report.html/toc

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Executive Summary 6
2.1 Exceptionally Large and Innovative Pipeline 6
2.2 Alignment of First-in-Class Molecular Target with Disease Causation 6
2.3 Highly Active Deals Landscape with Numerous Investment Opportunities 6
3 The Case for Innovation 7
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 8
3.3 Innovative First-in-Class Product Developments Remain Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation 9
3.5 Sustained Innovation in Breast Cancer 9
3.6 Report Guidance 9
4 Clinical and Commercial Landscape 11
4.1 Overview of Breast Cancer 11
4.2 Symptoms 11
4.3 Diagnosis 11
4.4 Etiology 12
4.4.1 Age and Gender 12
4.4.2 Genetics 12
4.4.3 Environmental 13
4.5 Pathophysiology 13
4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 13
4.5.2 Tumor Metabolic Shift 14
...

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1877885

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Identify leading products and key unmet needs within the market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com

This release was published on openPR.